April 22 (Bloomberg) -- Valeant Pharmaceuticals International offered to buy Allergan in a cash-and-stock deal valued at $45.7 billion that will give the Canadian company the Botox wrinkle treatment. Pershing Square Capital Management LP, the fund run by Bill Ackman, Allergan’s largest shareholder, supports the offer, Valeant said. Stephanie Ruhle reports on Bloomberg Television’s “In The Loop.” (Source: Bloomberg)
Lower Oil Prices Won't Curb Dominion LNG Exports: CEO
04:45 - Thomas Farrell, chief executive officer of Dominion Resources Inc., talks about the company's liquified natural-gas export terminal, natural-gas pipleline and the outlook for energy sources. Farrell speaks with Alix Steel on Bloomberg Television's "Bloomberg Markets." (Source: Bloomberg)
Will European Creditors Cave into Greece?
How Serious Is the SEC Probe of Pre-IPO Share Sales?
Is Bitcoin an Emerging Safe Haven Amid Greek Uncertainty?
Please upgrade your Browser
Your browser is out-of-date. Please download one of these excellent browsers: